1-13 of 13
Anthony Wang
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Real-World Response Rates across Lines of Therapy Among Patients with Relapsed/Refractory Follicular Lymphoma

Tycel Philips, Laurie H. Sehn, Anthony Wang, Junhua Yu, Elizabeth H. Marchlewicz, Rajesh Kamalakar, Kavita Sail, Donald Arnette, Shibing Yang, Alex Mutebi, Fernando Rivas Navarro, Gilles Salles
Journal: Blood
Blood (2023) 142 (Supplement 1): 1683.
https://doi.org/10.1182/blood-2023-180088
Published: 2023
Journal Articles

Practice Efficiency Associated with Epcoritamab for the Treatment of Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma from an Institutional Perspective

Matthew M. Lei, Qianyi Li, Ken O'Day, Kellie Meyer, Anthony Wang, Monika Jun
Journal: Blood
Blood (2023) 142 (Supplement 1): 7254.
https://doi.org/10.1182/blood-2023-181259
Published: 2023
Journal Articles

Efficacy of Subcutaneous Epcoritamab Vs Tisa-Cel in R/R LBCL CAR T-Naive and CAR T-Eligible Patients: An Indirect Comparison

Gilles Salles, Christopher P. Fox, Anthony Wang, Kavita Sail, Abualbishr Alshreef, Michael Moran, Alex Mutebi, Julie Blaedel, Viktor Chirikov, Wei-Jhih Wang, Catherine Thieblemont
Journal: Blood
Blood (2023) 142 (Supplement 1): 1733.
https://doi.org/10.1182/blood-2023-180047
Published: 2023
Journal Articles

Patterns of Care and Resource Use Among Elderly Relapsed/Refractory Follicular Lymphoma Patients: US Medicare Claims Analysis

Savreet Bains Chawla, Shibing Yang, Jing He, Monika Jun, Nicole Heaps, Anthony Wang, Junhua Yu, Chenxue Liang, Allison Keshishian, Jon Ukropec
Journal: Blood
Blood (2023) 142 (Supplement 1): 5158.
https://doi.org/10.1182/blood-2023-181854
Published: 2023
Journal Articles

Cebpβ/IL1/TNFα Positive Feedback Loop Drives Drug Resistance of BCL2 and MDM2 Inhibitors in Monocytic Leukemia Cells

Basil Allen, Daniel Bottomly, Anthony Wang, Thomas Koehnke, Lindsey Savoy, Peter Ryabini, Reid Chen, Kara Johnson, Stephen E. Kurtz, Anupriya Agarwal, Michelle Barton, Brian J. Druker, Ravi Majeti, Jeffrey W Tyner, Shannon K McWeeney, Haijiao Zhang
Journal: Blood
Blood (2023) 142 (Supplement 1): 2937.
https://doi.org/10.1182/blood-2023-178096
Published: 2023
Journal Articles

Effectiveness of Chemo-Immunotherapy (CIT) and Novel Therapies in Second or Later Line of Therapy (2L+) for Patients with Relapsed/Refractory (R/R) Aggressive Large B-Cell Lymphoma (LBCL)

Loretta J. Nastoupil, Clark R. Andersen, Amy Ayers, Yucai Wang, Thomas M. Habermann, Dai Chihara, Brad S. Kahl, Brian K. Link, Jonathon B. Cohen, Peter Martin, Izidore S. Lossos, Carla Casulo, Ruitao Lin, Ziyi Li, Melissa C. Larson, Matthew J. Maurer, Lynn Huynh, Chi Gao, Ramya Ramasubramanian, Mei Sheng Duh, Alex Mutebi, Tongsheng Wang, Monika Jun, Anthony Wang, Rajesh Kamalakar, Anupama Kalsekar, James R. Cerhan, Christopher R. Flowers
Journal: Blood
Blood (2023) 142 (Supplement 1): 309.
https://doi.org/10.1182/blood-2023-174497
Published: 2023
Journal Articles

Cost-Effectiveness of Epcoritamab in Relapsed or Refractory Diffuse Large B-Cell Lymphoma after at Least Two Lines of Therapy in the United States

Tingting Qu, Monika Jun, Anindit Chhibber, Alex Mutebi, Huimin Li, Yang Meng, Anthony Wang
Journal: Blood
Blood (2023) 142 (Supplement 1): 5089.
https://doi.org/10.1182/blood-2023-181177
Published: 2023
Journal Articles

Estimation of Relapsed/Refractory Follicular Lymphoma Patients on Therapy in the United States

Karissa Johnston, Mark Bennett, Savreet Bains Chawla, Shibing Yang, Anthony Wang, Junhua Yu, Monika Jun
Journal: Blood
Blood (2023) 142 (Supplement 1): 6148.
https://doi.org/10.1182/blood-2023-182030
Published: 2023
Journal Articles

Follicular Lymphoma Treatment Patterns and Outcomes over Time: A Real-World Analysis in the United States

Tycel Phillips, Junhua Yu, Rajesh Kamalakar, Kalatu R. Davies, Alex Mutebi, Savreet Bains Chawla, Donald Arnette, Syed Quadri, Anthony Wang
Journal: Blood
Blood (2022) 140 (Supplement 1): 5241–5243.
https://doi.org/10.1182/blood-2022-157773
Published: 2022
Journal Articles

Real-World Outcomes in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated with Standard of Care: A Cota Database Analysis

Andrew Ip, Alex Mutebi, Tongsheng Wang, Monika P. Jun, Anupama Kalsekar, Fernando Rivas Navarro, Anthony Wang, Rajesh Kamalakar, Mariana Sacchi, Brian Elliott
Journal: Blood
Blood (2022) 140 (Supplement 1): 6693–6694.
https://doi.org/10.1182/blood-2022-159569
Published: 2022
Journal Articles

Indirect Comparisons of the Efficacy of Subcutaneous Epcoritamab Vs Chemoimmunotherapy in Patients with Relapsed or Refractory Large B-Cell Lymphoma

Gilles Salles, Anthony Wang, Alex Mutebi, Abualbishr Alshreef, Kalatu R. Davies, Gijs van de Wetering, Viktor Chirikov
Journal: Blood
Blood (2022) 140 (Supplement 1): 10934–10935.
https://doi.org/10.1182/blood-2022-158028
Published: 2022
Journal Articles

Improvements in Lymphoma Symptoms and Health-Related Quality of Life in Patients with Relapsed or Refractory Large B-Cell Lymphoma Treated with Subcutaneous Epcoritamab (EPCORE NHL-1)

Tycel Phillips, Pieternella Lugtenburg, Anupama Kalsekar, Alex Mutebi, Anthony Wang, Julie Blaedel, Katherine Kosa, Susan Martin, Mariana Sacchi, Catherine Thieblemont
Journal: Blood
Blood (2022) 140 (Supplement 1): 8022–8023.
https://doi.org/10.1182/blood-2022-159544
Published: 2022
Journal Articles

Health Care Resource Utilization and Costs of CAR T Therapy in Patients with Large B-Cell Lymphoma: A Retrospective US Claims Database Analysis

Kalatu R. Davies, Rajesh Kamalakar, Junhua Yu, Yinan Huang, Anthony Wang, Kavita Sail, Thomas Doerr, Simon Sharmokh, Alex Mutebi, Gilles Salles
Journal: Blood
Blood (2022) 140 (Supplement 1): 5058–5059.
https://doi.org/10.1182/blood-2022-157758
Published: 2022